Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Academy: 200-day line · RSI
About the company
Moderna is a US biotech company built on mRNA technology. It became known for its Covid-19 vaccine. It also develops vaccines against RSV and flu as well as cancer and other therapies based on mRNA. As of Oct 11, 2026
As of Oct 11, 2026Fact sheet (from the annual report)Biotechnology and vaccines · Cambridge, USAfull fact sheet
The company develops mRNA-based vaccines and therapies for infectious diseases, oncology and rare diseases. It markets the vaccines Spikevax and mNEXSPIKE against COVID and mRESVIA against the respiratory virus RSV. Revenue in 2025 came largely from the COVID vaccines. According to the company, mNEXSPIKE, launched in 2025, was ahead of its other products in the US retail channel as of the report. Its research comprises programs in infectious diseases, oncology and rare diseases, partly together with Merck.
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Detected chart patterns
Double bottom on the daily chart, detected on Nov 4, 2026
Free with an account until Jan 31, 2027: all Premium features, no subscription and no card. Sign up free
Earlier patterns · Past performance, not a forecast
Earlier patternsChart patterns that were detected for this asset earlier, each with its outcome: target 1 reached, stop reached (invalid), time limit over or still open. A list of the past, not a forecast.Example: Example: “Flag, detected on 3 Sep, target 1 reached on 22 Sep” – describes that one case, not the next pattern.More in the Academy: Glossary
Trend by timeframeFor each timeframe (week, day, 4 hours): up when the close is above the SMA 200, the EMA 20 above the EMA 50 and the structure shows higher highs and lows. Down the other way round, otherwise mixed. No score, no forecast.Example: Week up, day up, 4 hours mixed → not aligned.More in the Academy: Lesson trend and market structure
1Wweekly candles↗ up
Close above the SMA 200
EMA 20 above the EMA 50
higher highs and higher lows
Price above the EMA 20 · above the EMA 50
Week to Nov 20, 2026
1Ddaily candles↔ mixed
Close above the SMA 200
EMA 20 above the EMA 50
Highs and lows mixed
Price below the EMA 20 · below the EMA 50
Daily candle of Nov 20, 2026
4H4-hour candles↔ mixed
Close above the SMA 200
EMA 20 below the EMA 50
higher highs and higher lows
Price below the EMA 20 · below the EMA 50
Candle from Nov 20, 2026, 19:30
Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up →
What does the daily chart show right now – line by line, without an overall verdict?
Technicals in plain words
Technicals in plain wordsFour lines on the daily chart – trend, momentum, volume, volatility –, each with its metric and threshold. We do not add the lines up or give a grade; they describe the price history so far.Example: RSI 64 → between 30 and 70, neither overbought nor oversold.More in the Academy: Lesson reading the RSI
Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.
vs. S&P 500 · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. S&P 500 · 6 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. sector · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
Trendabove SMA 200Price above the 200-day line – above it the long-term trend counts as up; ADX above 25 – a pronounced trend.
MomentumneutralRSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
Volumenot elevatedVolume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
VolatilityhighTypical daily range (ATR 14) above 4% of the price – high.
The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account.Sign up free
More depth
How we read the lines
Each line stands on its own – we do not add them up and give no grade.
Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
Against the sector median over 6 months: ran stronger.
All figures describe the price history so far – they do not say what happens next.
As of: daily candle of Nov 20, 2026 · from our daily candles
How did this asset do in each calendar month over the last 10 years?
Seasonality
SeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
For November, 7 of 10 years are available – too few to say anything (at least 8 needed).
Months mostly higher
5 of 10
Calendar months that closed higher in more than half of the years
You can see the median and range per month in percent with a free account.Sign up free
5/8Jan
3/8Feb
4/8Mar
5/8Apr
5/8May
4/8Jun
5/8Jul
3/8Aug
5/8Sep
4/8Oct
–Nov
–Dec
January: higher in 5 of 8 years
February: higher in 3 of 8 years
March: higher in 4 of 8 years
April: higher in 5 of 8 years
May: higher in 5 of 8 years
June: higher in 4 of 8 years
July: higher in 5 of 8 years
August: higher in 3 of 8 years
September: higher in 5 of 8 years
October: higher in 4 of 8 years
November (current month): too little data (7 years)
December: too little data (7 years)
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividendsMore depth
How we calculate
Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
Month
Years higher
January
5 of 8
February
3 of 8
March
4 of 8
April
5 of 8
May
5 of 8
June
4 of 8
July
5 of 8
August
3 of 8
September
5 of 8
October
4 of 8
November ●
too little data (7 years)
December
too little data (7 years)
Through October 2026 (last completed month) · from our daily candles
Opportunity at a glance Moderna
There is no opportunity card on 1-hour candles: we calculate patterns, targets and supports on the 4H, daily and weekly charts.
Pattern on the chart:Double bottom on the daily chart, detected on Nov 4, 2026 – Entry area, stop and targets are calculated. You see these and all other figures on the card with a free account.
What does this mean? The card sums up patterns, potential, risk and supports on the 4H, daily and weekly chart.
Potential to target 1●● %hidden4-hour or daily chart
Risk to stop
●● %hidden
Reward/risk
● : 1hidden
Remaining potential: moved since detection and still open to target 1 – each in % with timeframe.
Potential to target on the weekly chart●● %hiddenWeekly chart
Invalid below (weekly close)
●● %hidden
Supports below
3
Supports below with distance in %, timeframe and number of tests (possible levels to add).
Trend Trend by timeframeFor each timeframe (week, day, 4 hours): up when the close is above the SMA 200, the EMA 20 above the EMA 50 and the structure shows higher highs and lows. Down the other way round, otherwise mixed. No score, no forecast.Example: Week up, day up, 4 hours mixed → not aligned.More in the Academy: Lesson trend and market structure4H↔ mixed1D↔ mixed1W↗ up
In favour0 · Against2Points without chart-pattern detail – you see every point with figure and date with a free account
Calculated automatically by fixed rules – not investment advice. How we analyze
Potential
This shows the distance from the last close to the pattern’s target mark – a distance, not a return. Next to it the risk to the stop, each with the timeframe the figure comes from.
Supports below
Under “Long term” you find price areas below the price where it has already turned several times – with distance in percent, timeframe and number of tests. They describe where the price found support before.
For · Against
Fixed rules collect facts that speak for or against the picture, each with its date. There is deliberately no total and no grade – you do the weighing yourself.
My plan
“My plan” remembers your holding period and a target level of your own and lets you know when the price reaches the entry area. That and all figures of the card are available with a free account.
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Moderna · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 20, 2026.
Investor typeInvestor type (“lens”)You choose which style comes first: dividends, valuation, growth, quality or trading. Screener and stock page then show suggestions and “For you first”, with an account also matching columns and order. The lens unlocks nothing and changes no matches.Example: Lens “Dividends” → on the stock page first the streak without a cut, growth and cover of the dividend.More in the Academy: Guide fundamental analysis
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
✗not met: Profit in each of the last 5 fiscal years2 of 5
✗not met: Free cash flow positive in each of the last 3 fiscal years0 of 3
✓met: Equity ratio above 30%70.1%
Gross margin
55.3%Fiscal year 2025
All62medium
Rank 62 of 100: higher than 62% of 370 peers (All). medium.
Sector36medium
Rank 36 of 100: higher than 36% of 49 peers (Sector). medium.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Operating margin
−158.1%Fiscal year 2025
All4weak
Rank 4 of 100: higher than 4% of 470 peers (All). weak.
Sector3weak
Rank 3 of 100: higher than 3% of 54 peers (Sector). weak.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
−145.2%Fiscal year 2025
All4weak
Rank 4 of 100: higher than 4% of 584 peers (All). weak.
Sector4weak
Rank 4 of 100: higher than 4% of 63 peers (Sector). weak.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
−32.6%Fiscal year 2025
All5weak
Rank 5 of 100: higher than 5% of 544 peers (All). weak.
Sector5weak
Rank 5 of 100: higher than 5% of 54 peers (Sector). weak.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
Return on assets
−22.9%Fiscal year 2025 (total assets at year end)
All3weak
Rank 3 of 100: higher than 3% of 594 peers (All). weak.
Sector4weak
Rank 4 of 100: higher than 4% of 63 peers (Sector). weak.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
Equity ratio
70.1%Fiscal year 2025
All90strong
Rank 90 of 100: higher than 90% of 595 peers (All). strong.
Sector83strong
Rank 83 of 100: higher than 83% of 63 peers (Sector). strong.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
−106.2%Fiscal year 2025
All5weak
Rank 5 of 100: higher than 5% of 465 peers (All). weak.
Sector4weak
Rank 4 of 100: higher than 4% of 61 peers (Sector). weak.
Median Health Care: 14.5%
Free cash flow divided by revenue.
Free cash flow
−2.1B USDFiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 1 of 6 met · 1 without data
✗not met: Over 3 years, revenue grew by more than 5% per year−53.4%
✓met: Over 5 years, revenue grew by more than 5% per year+19.3%
–no data: Over 10 years, revenue grew by more than 5% per yearno comparable figures over 10 years
✗not met: Over 3 years, EPS grew by more than 5% per yearno earnings per share in the last fiscal year
✗not met: Over 5 years, EPS grew by more than 5% per yearno earnings per share in the last fiscal year
✗not met: Revenue rose in at least 4 of the last 5 fiscal years2 of 5
✗not met: Revenue rose in the last fiscal year−39.9%
Revenue growth 3 years
−53.4%per year
All0weak
Rank 0 of 100: higher than 0% of 578 peers (All). weak.
Sector1weak
Rank 1 of 100: higher than 1% of 62 peers (Sector). weak.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+19.3%per year
All81strong
Rank 81 of 100: higher than 81% of 549 peers (All). strong.
Sector94strong
Rank 94 of 100: higher than 94% of 60 peers (Sector). strong.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
Dividend 0 of 1 met · 6 without data
✗not met: Pays a dividendno dividend per share reported for the last fiscal year
–no data: Payout ratio at most 60% of earningspays no dividend
–no data: Dividend paid in each of the last 5 fiscal yearspays no dividend
–no data: Dividend per share never lowered in the last 5 fiscal yearspays no dividend
–no data: Dividend per share higher than 5 years agopays no dividend
–no data: Free cash flow per share covers the dividendpays no dividend
–no data: Dividends paid over the last 5 years covered by free cash flowpays no dividend
Financial strength 4 of 6 met
✗not met: Piotroski F-Score at least 7 of 92 of 9
✓met: Long-term debt no higher than equity0.07
✓met: Current assets cover current liabilities3.29
✓met: Positive equity8.7B USD
✓met: In 5 years, share count up by at most 5%+2.1%
✗not met: Free cash flow positive in the last fiscal year−2.1B USD
Piotroski F-Score
2 of 9Fiscal year 2025
All1weak
Rank 1 of 100: higher than 1% of 310 peers (All). weak.
Sector1weak
Rank 1 of 100: higher than 1% of 47 peers (Sector). weak.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.07at fiscal year end
All91strong
Rank 91 of 100: lower than 91% of 486 peers (All). strong.
Sector89strong
Rank 89 of 100: lower than 89% of 50 peers (Sector). strong.
Median Health Care: 0.66
Long-term financial debt divided by equity.
Liquidity (current ratio)
3.29at fiscal year end
All88strong
Rank 88 of 100: higher than 88% of 513 peers (All). strong.
Sector88strong
Rank 88 of 100: higher than 88% of 63 peers (Sector). strong.
Median Health Care: 1.58
Current assets divided by current liabilities.
Change in share count
+2.1%in 5 years
All33medium
Rank 33 of 100: lower than 33% of 507 peers (All). medium.
Sector19weak
Rank 19 of 100: lower than 19% of 59 peers (Sector). weak.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
✗not met: Profit in the last fiscal year (positive return on assets)
✗not met: Positive operating cash flow
✗not met: Return on assets higher than the prior year
✓met: Operating cash flow higher than net income
✗not met: Long-term debt relative to total assets fell
✗not met: Liquidity (current assets / current liabilities) rose
✗not met: No additional shares (diluted share count did not rise)
✓met: Gross margin higher than the prior year
✗not met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
Light green: Revenue grew over 5 years (+19.3% per year), at least as fast as the sector median.
Light red: Loss in the last fiscal year.
Light green: Debt not higher than usual in the sector.
Light red: Profit in 2 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
010B20B
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 108.4M USD · Net income −216.2M USD · Net margin −199.5%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 205.8M USD · Net income −255.9M USD · Net margin −124.3%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 135.1M USD · Net income −384.7M USD · Net margin −284.8%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 60.2M USD · Net income −514.0M USD · Net margin −853.7%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 803.4M USD · Net income −747.1M USD · Net margin −93.0%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 18.5B USD · Net income 12.2B USD · Net margin 66.1%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 19.3B USD · Net income 8.4B USD · Net margin 43.4%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 6.8B USD · Net income −4.7B USD · Net margin −68.8%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 3.2B USD · Net income −3.6B USD · Net margin −110.0%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%
Margin
−199%−124%−285%−854%−93%66%43%−69%−110%−145%
RevenueNet incomeNet margin (below)in USD
−2B02B4B
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 2.8B USD · Net income 217.0M USD · Net margin 7.7% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 167.0M USD · Net income −1.2B USD · Net margin −703.6%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 241.0M USD · Net income −1.3B USD · Net margin −530.7%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 1.9B USD · Net income 13.0M USD · Net margin 0.7%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 966.0M USD · Net income −1.1B USD · Net margin −115.9% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 108.0M USD · Net income −971.0M USD · Net margin −899.1%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 142.0M USD · Net income −825.0M USD · Net margin −581.0%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 1.0B USD · Net income −200.0M USD · Net margin −19.7%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 678.0M USD · Net income −826.0M USD · Net margin −121.8% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 389.0M USD · Net income −1.3B USD · Net margin −345.2%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 145.0M USD · Net income −782.0M USD · Net margin −539.3%
Q3/26Quarter Q3/26 (Jul 1, 2026 – Sep 30, 2026): Revenue 1.3B USD · Net income 162.0M USD · Net margin 12.3%
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%
How has it gone since the last annual report?
Trailing 12 months and quarters
Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Revenue in the quarter to Sep 2026 +29.2% vs. the same quarter a year earlier; grown for 3 quarters in a row.
Revenue 12 months vs. prior 12Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Free cash flow margin 12 monthsFree cash flowCash from operations minus investment in property, plant and equipment. It shows how much money is left over – for repaying debt, dividends or share repurchases.Example: Operating cash flow 120 million euros, investments 45 million euros → free cash flow 75 million euros.More in the Academy: Guide fundamental analysis
−78.0%
Fiscal year 2025: no value
More depth
Calculation of the 12 months to Sep 30, 2026
Revenue: fiscal year to Dec 31, 2025 1.9B USD + year to date to Sep 30, 2026 1.8B USD − same period a year earlier to Sep 30, 2025 1.3B USD = 2.5B USD
Net income: fiscal year to Dec 31, 2025 −2.8B USD + year to date to Sep 30, 2026 −2.0B USD − same period a year earlier to Sep 30, 2025 −2.0B USD = −2.8B USD
Operating cash flow: fiscal year to Dec 31, 2025 −1.9B USD + year to date to Sep 30, 2026 −2.7B USD − same period a year earlier to Sep 30, 2025 −2.8B USD = −1.8B USD
Capital expenditure: fiscal year to Dec 31, 2025 192.0M USD + year to date to Sep 30, 2026 146.0M USD − same period a year earlier to Sep 30, 2025 153.0M USD = 185.0M USD
By quarter (latest first, amounts in USD)
Quarter
Revenue
vs. year ago
Net income
Margin
Jul–Sep 26
1.3B
+29.2%
162.0M
12.3%
Apr–Jun 26
145.0M
+2.1%
−782.0M
–
Jan–Mar 26
389.0M
+260.2%
−1.3B
–
Oct–Dec 25*
678.0M
−29.8%
−826.0M
–
Jul–Sep 25
1.0B
−45.4%
−200.0M
−19.7%
Apr–Jun 25
142.0M
−41.1%
−825.0M
–
Jan–Mar 25
108.0M
−35.3%
−971.0M
–
Oct–Dec 24*
966.0M
−65.6%
−1.1B
–
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 30, 2026, filed on Nov 6, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Earnings quality
There was no profit in fiscal year 2025; operating income does not cover interest.
Cash flow ÷ profitCash flow ÷ profitOperating cash flow divided by group profit. From 1.0, at least as much cash came in as profit was reported; below that, profit may sit in receivables or inventories, and non-cash gains or one-off payments also push the ratio down. Depreciation and stock-based pay lift it.Example: Operating cash flow €120m, group profit €100m → 1.20x.More in the Academy: Lesson earnings quality
–
no profit in fiscal year 2025
Interest coverageInterest coverageOperating income divided by interest expense: how many times the core business earns its interest. From 5x we count interest as well covered, below 2x as thinly covered.Example: Operating income €50m, interest expense €5m → 10.0x.More in the Academy: Lesson earnings quality
negative
25
operating income negative · interest paid per cash flow statement · 3 years: negative
Tax rateTax rateIncome taxes divided by profit before tax, in percent. If the SEC data lack it, we approximate it as group profit plus taxes; minority interests, discontinued operations, one-off items and tax credits can shift the rate.Example: Taxes €21m, net income €79m → 21 : 100 = 21%.More in the Academy: Lesson earnings quality
–
no profit before tax
More depth
Calculation for fiscal year 2025
Operating cash flow −1.9B USD ÷ Net income −2.8B USD = no ratio (no profit)
Operating income −3.1B USD ÷ interest paid per cash flow statement 10.0M USD = negative
Taxes 54.0M USD ÷ profit before tax −2.8B USD = no rate (no profit before tax)
By fiscal year
FY
Cash flow ÷ profit
Interest coverage
Tax rate
2025
–
negative
–
2024
–
negative
–
2023
–
negative
–
2022
0.60x
over 100x
12.7%
2021
1.12x
over 100x
8.2%
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
Consistency
In 10 fiscal years 8 loss years; 5 years with lower revenue across 9 years with a prior-year figure.
Loss yearsLoss yearsFiscal years that ended with a loss on the bottom line (net income below zero). Few loss years over a long period show how evenly a company has earned so far – they say nothing about the future.Example: Loss only in fiscal year 2020 → 1 of 10.More in the Academy: Lesson revenue, profit and margin
8 of 10
net income below zero
Years with lower revenueYear with lower revenueA fiscal year in which revenue was lower than in the prior year. Only years for which the prior year’s revenue is also reported are counted.Example: Revenue 100 → €96m → one year with lower revenue.More in the Academy: Lesson revenue, profit and margin
5 of 9
revenue below the prior year
Net margin rangeNet margin rangeHighest minus lowest net margin of the fiscal years shown, in percentage points. A small range means the share of profit in revenue stayed similar over the years.Example: Net margins between 18.2% and 26.4% → range 8.2 percentage points.More in the Academy: Lesson revenue, profit and margin
265.5 percentage points
from −199.5% to 66.1%
▾▾▾▾▾20162025Net margin by fiscal year · ▾ revenue below the prior yearMore depth
By fiscal year
FY
Revenue vs. prior year
Net margin
2025
−39.9%
−145.2%
2024
−52.7%
−110.0%
2023
−64.4%
−68.8%
2022
+4.3%
43.4%
2021
+2,199.1%
66.1%
2020
+1,234.3%
−93.0%
2019
−55.4%
–
2018
−34.4%
–
2017
+89.9%
−124.3%
2016
–
−199.5%
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Since when has today’s status held?
Check status by fiscal year
Check status by fiscal yearPoints of the four quality checks without price data by fiscal year: earlier years recalculated as of the filing date of their annual report with the figures known then, the latest year with today’s status. This shows since when today’s status has held.Example: Quality 7 of 8 in the annual reports 2022 to 2025, still 6 of 8 in 2021 → since fiscal year 2022.More in the Academy: Guide fundamental analysis
Quality: 2 of 8 criteria in every annual report since 2024; Financial strength in fiscal year 2025: 4 of 6 (prior year 2 of 5).
Quality2 of 8since FY 2024 · before that 1 of 8
Growth1 of 6since FY 2024 · before that 2 of 5
Dividend0 of 1in every annual report since 2021
Financial strength4 of 6since FY 2025 · before that 2 of 5
More depth
Criteria met by fiscal year (met/with data)
Check
2021
2022
2023
2024
2025
Quality
6/8
7/8
1/8
2/8
2/8
Growth
3/4
3/4
2/5
1/6
1/6
Dividend
0/1
0/1
0/1
0/1
0/1
Financial strength
3/3
3/4
2/4
2/5
4/6
Fiscal year 2025 with today’s status of the checks without price data (for accounts, the badges above also count P/E/PEG and dividend yield).
Earlier years as of the filing date of their annual report: FY 2024 on Feb 21, 2025, FY 2023 on Feb 23, 2024, FY 2022 on Feb 24, 2023, FY 2021 on Feb 25, 2022.
Recalculated only with SEC filings up to the respective filing date – later corrections are left out. Without price-based criteria (P/E, dividend yield); criteria without data do not count.
As of annual reports 2021–2025 · Source: SEC filings
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 55.3 USD gross profit remained.
2016Fiscal year 2016: Operating cash flow 66.7M USD · Capital expenditure 33.1M USD · Free cash flow 33.6M USD
2017Fiscal year 2017: Operating cash flow −331.5M USD · Capital expenditure 58.4M USD · Free cash flow −389.9M USD
2018Fiscal year 2018: Operating cash flow −330.9M USD · Capital expenditure 105.8M USD · Free cash flow −436.6M USD
2019Fiscal year 2019: Operating cash flow −459.0M USD · Capital expenditure 31.6M USD · Free cash flow −490.5M USD
2020Fiscal year 2020: Operating cash flow 2.0B USD · Capital expenditure 67.4M USD · Free cash flow 2.0B USD
2021Fiscal year 2021: Operating cash flow 13.6B USD · Capital expenditure 284.0M USD · Free cash flow 13.3B USD
2022Fiscal year 2022: Operating cash flow 5.0B USD · Capital expenditure 400.0M USD · Free cash flow 4.6B USD
2023Fiscal year 2023: Operating cash flow −3.1B USD · Capital expenditure 707.0M USD · Free cash flow −3.8B USD
2024Fiscal year 2024: Operating cash flow −3.0B USD · Capital expenditure 1.1B USD · Free cash flow −4.1B USD
2025Fiscal year 2025: Operating cash flow −1.9B USD · Capital expenditure 192.0M USD · Free cash flow −2.1B USD
Share count
The share count rose in 5 years by 2.1% – more new shares were issued than repurchased (dilution).
Diluted share count
0200M400M600M
2016Fiscal year 2016: Diluted share count not available
2017Fiscal year 2017: Diluted share count not available
2018Fiscal year 2018: Diluted share count not available
2019Fiscal year 2019: Diluted share count 331.0M
2020Fiscal year 2020: Diluted share count 381.0M
2021Fiscal year 2021: Diluted share count 431.0M
2022Fiscal year 2022: Diluted share count 416.0M
2023Fiscal year 2023: Diluted share count 382.0M
2024Fiscal year 2024: Diluted share count 384.0M
2025Fiscal year 2025: Diluted share count 389.0M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Metrics chart
Metrics chartUp to three metrics stacked, each with its own axis, over the same fiscal years. Optionally a second stock (dashed or hatched) and today’s sector median as a mark in the latest year – we do not have earlier medians.Example: Revenue rises, net margin falls, share count falls → more business, less profit per unit of revenue, fewer shares (mostly through buybacks).More in the Academy: Guide fundamental analysis
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
Revenue
Revenue rose in 5 years from 803.4M USD to 1.9B USD.
MRNAin USD
05B10B15B20B
2016Fiscal year 2016: MRNA 108.4M USD
2017Fiscal year 2017: MRNA 205.8M USD
2018Fiscal year 2018: MRNA 135.1M USD
2019Fiscal year 2019: MRNA 60.2M USD
2020Fiscal year 2020: MRNA 803.4M USD
2021Fiscal year 2021: MRNA 18.5B USD
2022Fiscal year 2022: MRNA 19.3B USD
2023Fiscal year 2023: MRNA 6.8B USD
2024Fiscal year 2024: MRNA 3.2B USD
2025Fiscal year 2025: MRNA 1.9B USD
Net margin
The net margin fell in 5 years from −93.0% to −145.2%.
MRNASector today 13.9%Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
−200%−100%0%100%
2016Fiscal year 2016: MRNA −199.5%
2017Fiscal year 2017: MRNA −124.3%
2018Fiscal year 2018: MRNA not available
2019Fiscal year 2019: MRNA not available
2020Fiscal year 2020: MRNA −93.0%
2021Fiscal year 2021: MRNA 66.1%
2022Fiscal year 2022: MRNA 43.4%
2023Fiscal year 2023: MRNA −68.8%
2024Fiscal year 2024: MRNA −110.0%
2025Fiscal year 2025: MRNA −145.2% · Sector today 13.9%
Free cash flow margin
The free cash flow margin fell in 4 years from 72.2% to −106.2%.
MRNASector today 14.9%
−200%−100%0%100%
2016Fiscal year 2016: MRNA 31.0%
2017Fiscal year 2017: MRNA −189.4%
2018Fiscal year 2018: MRNA not available
2019Fiscal year 2019: MRNA not available
2020Fiscal year 2020: MRNA not available
2021Fiscal year 2021: MRNA 72.2%
2022Fiscal year 2022: MRNA 23.8%
2023Fiscal year 2023: MRNA −55.9%
2024Fiscal year 2024: MRNA −125.3%
2025Fiscal year 2025: MRNA −106.2% · Sector today 14.9%
Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
Dividend at a glance
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
Valuation against its own history
Valuation against its own historyWhere P/E, P/S or price/free cash flow stands today compared with the median of the company’s own last 5 fiscal years, in percent. Up to 10% deviation counts as “about at the median”. Describes only the position, not a judgement on an appropriate price.Example: P/E today 22, own 5-year median 27 → 22 ÷ 27 − 1 = −18.5%, so below the median.More in the Academy: Lesson cheaper or pricier than usual?
There is no comparison for the P/E: the last fiscal year ended with a loss.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation.Sign up free
Source: SEC filings and our daily candles
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Dividend per share
nonepays no dividend
To shareholders (5 years)
5.3B USD100% through repurchases
Share count over 5 years
+2.1%more shares – dilution
What goes back to shareholders
Over 5 years, 5.3B USD went back to shareholders, 100% of it through share repurchases. That is 67% of the free cash flow of those years.
2016Fiscal year 2016: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 33.6M USD
2017Fiscal year 2017: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow −389.9M USD
2018Fiscal year 2018: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 563.0M USD · Free cash flow −436.6M USD
2019Fiscal year 2019: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 0.0 USD · Free cash flow −490.5M USD
2020Fiscal year 2020: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 1.9B USD · Free cash flow 2.0B USD
2021Fiscal year 2021: Dividends paid not available · Share repurchases 857.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 13.3B USD
2022Fiscal year 2022: Dividends paid not available · Share repurchases 3.3B USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 4.6B USD
2023Fiscal year 2023: Dividends paid not available · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow −3.8B USD
2024Fiscal year 2024: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow −4.1B USD
2025Fiscal year 2025: Dividends paid not available · Share repurchases 2.0M USD · New shares issued (including employee plans) not available · Free cash flow −2.1B USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.Log in
Sector comparison
Moderna next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
Sector comparison MRNA, sector Health Care; last row: sector median
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+19.3%per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 19.3% per year on average – at least as fast as the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light gray: not computable
–per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 145.16 USD. Five years ago the margin was −93.0%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light green: lower than sector
0.43latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.43 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light red: 8 loss years
2 of 10fiscal years with a profit
What does this mean? In 2 of the last 10 fiscal years the bottom line showed a profit. 8 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
1.9B USD
Revenue vs. prior year
−39.9%
Net income (FY)
−2.8B USD
Net income vs. prior year
–
EPS (FY)
-7.26 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 20, 2026 · Balance sheet Sep 30, 2026 (filed Nov 6, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
1.9B
−2.8B
−145.2%
−7.26
–
–
2024
Dec 31, 2024
3.2B
−3.6B
−110.0%
−9.28
–
–
2023
Dec 31, 2023
6.8B
−4.7B
−68.8%
−12.33
–
–
2022
Dec 31, 2022
19.3B
8.4B
43.4%
20.12
–
–
2021
Dec 31, 2021
18.5B
12.2B
66.1%
28.29
–
–
2020
Dec 31, 2020
803.4M
−747.1M
−93.0%
−1.96
–
–
2019
Dec 31, 2019
60.2M
−514.0M
−853.7%
−1.55
–
–
2018
Dec 31, 2018
135.1M
−384.7M
−284.8%
–
–
–
2017
Dec 31, 2017
205.8M
−255.9M
−124.3%
–
–
–
2016
Dec 31, 2016
108.4M
−216.2M
−199.5%
–
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q3/26
Sep 30, 2026
1.3B
162.0M
12.3%
0.38
–
–
Q2/26
Jun 30, 2026
145.0M
−782.0M
−539.3%
−1.97
–
–
Q1/26
Mar 31, 2026
389.0M
−1.3B
−345.2%
−3.40
–
–
Q4/25*
Dec 31, 2025
678.0M
−826.0M
−121.8%
–
–
–
Q3/25
Sep 30, 2025
1.0B
−200.0M
−19.7%
−0.51
–
–
Q2/25
Jun 30, 2025
142.0M
−825.0M
−581.0%
−2.13
–
–
Q1/25
Mar 31, 2025
108.0M
−971.0M
−899.1%
−2.52
–
–
Q4/24*
Dec 31, 2024
966.0M
−1.1B
−115.9%
–
–
–
Q3/24
Sep 30, 2024
1.9B
13.0M
0.7%
0.03
–
–
Q2/24
Jun 30, 2024
241.0M
−1.3B
−530.7%
−3.33
–
–
Q1/24
Mar 31, 2024
167.0M
−1.2B
−703.6%
−3.07
–
–
Q4/23*
Dec 31, 2023
2.8B
217.0M
7.7%
–
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Insider purchases and sales on the market over 3, 6 and 12 months
Period
Purchases
Sales
Net
3 months
$00 people
$50.8M3 people
−$50.8M
6 months
$00 people
$86.0M4 people
−$86.0M
12 months
$00 people
$98.5M6 people
−$98.5M
Latest transactions
Nov 17, 2026Hoge StephenOfficerOpen-market sale · 10b5-1 plan157 shares · $33.6K · SEC
Nov 17, 2026Hoge StephenOfficerOpen-market sale · 10b5-1 plan5,082 shares · $1.1M · SEC
Nov 17, 2026Hoge StephenOfficerOpen-market sale · 10b5-1 plan33,976 shares · $7.2M · SEC
Nov 16, 2026Hoge StephenOfficerOpen-market sale · 10b5-1 plan39,160 shares · $8.6M · SEC
Oct 15, 2026Hoge StephenOfficerOpen-market sale · 10b5-1 plan39,145 shares · $8.6M · SEC
Oct 14, 2026Hoge StephenOfficerOpen-market sale · 10b5-1 plan450 shares · $96.4K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Which superinvestors hold Moderna?
Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
Trend score +30
Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)-15
Highs and lows+10
Price change 60 days+15
Volatility and trend strength
ADX 14 (trend strength)pronounced (above 25)
Price change 60 daysup
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.